Business Context and Reporting Period
This Form 8-K is a current report filed by Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) on August 31, 2025. The filing addresses a specific corporate governance event under Item 5.02 regarding the departure of a director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a personnel change and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the resignation of Steven Richards as a director of the Company, effective August 31, 2025. The Company explicitly states that the resignation is not due to any disagreements with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook, or new risk factors. The document notes that the report was signed by Christopher Cooper in his capacity as Interim Chief Executive Officer.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Richards' resignation.
- Confirm the status and duration of Christopher Cooper's role as Interim CEO.
- Review recent press releases or other filings to determine if the director departure is part of a broader strategic shift.